KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA by Del Re, M. et al.
Session H. Lung cancer
H34 KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC:
an analysis on circulating tumor DNA
M. Del Re1, M. Tiseo2, A. D’Incecco3, A. Camerini4, I. Petrini5, M. Lucchesi5,
A. Inno6, D. Spada7, P. Bordi2, E. Vasile5, V. Citi1, G. Malpeli8, E. Testa7, S. Gori6,
A. Falcone5, D. Amoroso4, A. Chella9, F. Cappuzzo3, A. Ardizzoni10, A. Scarpa8,
R. Danesi1
1Clinical Pharmacology Unit, Department of Clinical and Experimental Medicine,
University of Pisa, Pisa
2Medical Oncology Unit, Azienda Ospedaliero-Universitaria, Parma
3Medical Oncology Unit, AUSL6, Istituto Toscano Tumori, Livorno
4Medical Oncology Unit, AUSL12, Istituto Toscano Tumori, Lido di Camaiore
5Medical Oncology Unit 2, AOUP, Istituto Toscano Tumori, Pisa
6Medical Oncology Unit, Ospedale Sacro Cuore, Negrar
7Medical Oncolgy Unit, Ospedale Santa Maria della Misericordia, Urbino
8ARC-NET Research Centre and Department of Pathology and Diagnostics, AOU,
Verona
9Lung Diseases Unit, AOUP, Pisa
10Medical Oncology Unit, AOU, Ospedale S. Orsola Malpighi, Bologna
Background: Activating mutations of KRAS oncogene drive resistance to EGFR
inhibition by providing an alternative signal transduction pathway [1]. In non-small
cell lung cancer (NSCLC), the efficacy of treatment with EGFR tyrosine kinase
inhibitors (EGFR-TKIs) depends on activating EGFRmutations that are mutually
exclusive with KRASmutations. However, pharmacological inhibition of EGFR
signaling has the potential to select cells whose growth may depend, at least in part, on
alternative proliferation pathways or continued EGFR signaling due to the c.2369C > T
(p.T790M) gatekeeper mutation within the ATP-binding pocket of EGFR. NSCLC
heterogeneity can drive the therapeutic decisions; therefore, tissue availability is
increasingly recognized as a crucial issue [2]. Unfortunately, the location of the tumor
and the risk of complications are serious limitations to re-biopsies in NSCLC.
Alternatively, the detection of somatic mutations in cell-free tumor DNA (cftDNA)
released in plasma could be instrumental for a better understanding of the genetic
modifications driven by the selective pressure of drug treatments on NSCLC [3].
Material and methods: This study used cell-free circulating tumor DNA (cftDNA) to
evaluate the appearance of codon 12 KRAS and p.T790M EGFRmutations in 33
advanced NSCLC patients that progressed after an EGFR-TKI. Six ml of blood samples
were drawn from patients at disease progression and cftDNAwas extracted by
Circulating Nucleic Acid extraction kit (Qiagen) and analysed by digital droplet PCR
(BioRad).
Results: KRASmutation at codon 12 alone or in combination with p.T790M was
demonstrated in 3 (9.1%) and 13 patients (39.4%), respectively. p.T790M was detected
in 11 subjects (33.3%) alone and in 13 patients (39.4%) with mutant KRAS. Six patients
(18.2%) were negative for both KRAS and p.T790M. In 8 subjects paired tumor
re-biopsy/plasma samples were available; the percent concordance of tissue/plasma was
62,5% for p.T790M and 37,5% for KRAS.
Conclusions: In conclusion, mutation of KRAS could be an additional mechanism of
escape to EGFR-TKI and cftDNA is a feasible approach to monitor the molecular
development of drug resistance. Therefore, the clinical relevance of this finding,
expecially for what concerns mutKRAS, needs to be evaluated prospectively.
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